{"analyses":[{"ciLowerLimit":"0.13","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.45","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":".0001","paramType":"Hazard Ratio (HR)","paramValue":"0.24","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.13","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.43","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":".0001","paramType":"Hazard Ratio (HR)","paramValue":"0.24","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"The number of events is too low to estimate this parameter.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"There was insufficient follow-up time to estimate the upper limit.","groupId":"OG001","lowerLimit":"27.8","upperLimit":"NA","value":"44.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"title":"Stage II-IIIA population"},{"categories":[{"measurements":[{"comment":"The number of events is too low to estimate this parameter.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"There was insufficient follow-up time to estimate the upper limit.","groupId":"OG001","lowerLimit":"28.5","upperLimit":"NA","value":"41.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"title":"ITT population"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"description":"DFS, defined as the time from randomization to the first documented recurrence of disease or new primary NSCLC as determined by the investigator through use of an integrated assessment of radiographic data, biopsy sample results (if clinically feasible), and clinical status or death from any cause, whichever occurs first","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 600 mg oral alectinib twice daily (BID) for 2 years","id":"OG000","title":"Alectinib"},{"description":"Participants received platinum-based chemotherapy for 4 cycles (cycle length = 21 days).","id":"OG001","title":"Platinum-Based Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"The ITT population consisted of all randomized participants, whether or not the participant received the assigned treatment.\n\nThe Stage II-IIIa population consisted of all participants in the ITT population with Stage II-IIIa NSCLC.","reportingStatus":"POSTED","timeFrame":"Approximately 58 months","title":"Disease-free Survival (DFS), as Assessed by the Investigator","type":"PRIMARY","unitOfMeasure":"months"}